Q2 2024
Released Nov 9, 2023, before the open
10-Q filed Nov 9, 2023, 40 days after period end · 0001764013-23-000133
Q2 2024 · 10-Q
Revenue—
Net Income-$58.66M-$58.66M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.45-$0.45 N/M vs Q2 2023N/M vs Q1 2024
Operating Cash Flowderived-$60,060,000N/M
Free Cash Flowderived-$60,094,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2018 |
|---|---|---|---|---|
| Net Income | -$58.66M | -$47.93M | -$37.70M | -$6.35M |
| EPS Diluted | -$0.45 | -$0.41 | -$0.35 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR